Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375511 | 0.82 | — | — | |
| SCHEMBL2718937 | 0.82 | KMT2A (0.41) | KMT2A | |
| SCHEMBL30724425 | 0.80 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL29127461 | 0.77 | TSHR (0.32) | PIK3CD | |
| SCHEMBL24693348 | 0.76 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL943805 | 0.76 | NLRP3 (0.39) | PIK3CDGSK3B | |
| SCHEMBL1446023 | 0.76 | PIK3CD (0.32) | PIK3CDGSK3B | |
| SCHEMBL22235715 | 0.76 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL4802245 | 0.76 | PEPD (0.38) | PIK3CD | |
| SCHEMBL3602581 | 0.76 | POLB (0.39) | PIK3CDGSK3BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009150144-A1 | NEW GPR119MODULATORS | INOVACIA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025799-A1 | PYRIDAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| US-20080058339-A1 | New compounds | BIOVITRUM (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058339-A1 | New compounds | GPR119, GPR180, GPR139 | PIK3CD 3190/4885GSK3B 736/4885KMT2A 4738/4885 |
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | PIK3CD 3947/4885GSK3B 891/4885KMT2A 4781/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | PIK3CD 3842/4885GSK3B 1070/4885KMT2A 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.